What's the best AI tool for digital pathology and tumor detection in a lab?

If you mean AI for a real pathology laboratory—not just research image analysis—I’d put PathAI and Paige at the top of the shortlist, with the best choice depending on whether you want broad tumor triage or a highly validated cancer-specific diagnostic tool.

My top picks

1. PathAI — best overall lab platform

• AISight Dx is an FDA-cleared digital pathology image-management platform for primary diagnosis in the U.S.
• TumorDetect automatically flags H&E cases likely to contain malignant tumor and prioritizes them for pathologist review. It covers breast, lung, prostate, colon, skin, stomach, duodenum and esophagus, with additional tumor types planned.
• AIM-TumorCellularity is particularly interesting if your lab does molecular testing/NGS: it estimates tumor area and tumor-cell percentage from whole-slide H&E images.
• PathAI has also been deploying AISight Dx and AI algorithms in large health-system laboratories, including a 2026 MedStar deployment.

Important: PathAI's current TumorDetect is listed as For Research Use Only, not for diagnostic procedures. PathAI 2. Paige — best for clinically validated cancer detection

• Paige Prostate Detect is particularly strong: it was the first AI pathology application FDA-authorized to aid in primary diagnosis of prostate cancer.
• Paige also has PanCancer Detect, designed to identify suspicious regions across multiple tissue types; it has FDA Breakthrough Device Designation.
• Its FullFocus viewer is FDA-cleared and integrates AI findings directly into slide review.

3. Ibex Medical Analytics — worth evaluating for automated cancer detection

• Ibex's Galen platform has strong evidence around cancer detection, particularly prostate pathology. A recent review reports FDA approval for its prostate AI and high sensitivity/specificity in validation studies.

What I'd choose

The key distinction is "AI that detects tumor" vs. "AI that is legally/clinically usable for diagnosis." A lot of impressive pathology AI is still RUO, so I would not choose based on model accuracy alone.

If you tell me what tumors you care about (e.g., breast, prostate, lung, colon), your scanner (Leica/Hamamatsu/Roche/Philips), and whether this is a CLIA clinical lab or research lab, I can narrow this to the best 2–3 systems and compare FDA status, accuracy, integrations, workflow, and likely cost.

Choosing the "best" AI tool for digital pathology and tumor detection depends heavily on your lab’s primary specialty (e.g., prostate, breast, GI), regulatory requirements, and existing scanner/LIMS infrastructure. Rather than a single universal winner, the market features a few clinical-grade powerhouses recognized for regulatory clearance, robust validation, and diagnostic accuracy.

• Paige (Paige.ai) : Widely considered a pioneer in the space, Paige made history with the first FDA-authorized AI application for primary pathology diagnosis (Paige Prostate ). Their suite covers prostate, breast, and GI tissues, helping highlight minute or hidden foci of cancer on whole-slide images. They also partner heavily with major diagnostics networks like Quest Diagnostics , making them a robust choice for high-throughput commercial labs.
• Ibex Medical Analytics : Ibex’s Galen platform is a leading choice, particularly for comprehensive second-opinion and primary diagnosis workflows in breast, prostate, and gastric cancer. Ibex is heavily deployed in routine clinical labs globally, scaling rapidly due to deep-learning models trained on massive multi-site datasets.
• PathAI : Known for its powerful AI-driven image management and diagnostic support tools, PathAI excels not just in clinical assistance to reduce inter-reader variability, but also in biopharma partnerships and companion diagnostics development.
• Aiforia : Excellent for labs looking for flexibility and deep learning across diverse tissue types. Aiforia offers CE-IVD marked clinical AI solutions (such as for breast and prostate cancer) alongside platforms that allow research and clinical labs to train and deploy their own custom AI models using advanced architectures like Vision Transformers.
• Mind Peak : A strong contender if your lab focuses heavily on automated immunohistochemistry (IHC) quantification (scoring HER2, PD-L1, ER/PR, Ki67). They provide turnkey background AI integration to standardize biomarker scoring and cut down subjective variance.

If you can share:

• Your lab's main specialty or tissue focus (e.g., prostate, general surgical, oncology trials)
• Whether you need CE-IVD/FDA clearance for primary diagnosis or research-only use
• Your current whole-slide scanner hardware

I can give you a more targeted recommendation on which platform fits your workflow best.

Paige AI (Paige Prostate/Full Suite) and PathAI (AISight) are among the leading regulatory-cleared AI platforms for digital pathology and tumor detection in clinical laboratory settings.

Top AI Tools for Digital Pathology

Key Considerations for Your Lab

• Integration: Ensure the software works with your lab's specific whole slide scanner (e.g., Leica, Philips, Hamamatsu) and Picture Archiving and Communication System (PACS).
• Regulatory Clearance: Look for FDA clearance or CE-IVD marking if you intend to use the tool for primary diagnosis rather than strictly for research or secondary review.
• Assay Compatibility: Check if the tool specializes in standard H&E staining or advanced immunohistochemistry (IHC) biomarker counting.

If you can share what specific cancer types or stain types (H&E vs. IHC) your lab focuses on most, I can provide a more tailored vendor recommendation.

If you're talking about a real clinical pathology lab using whole-slide images (WSIs) to detect tumors, my shortlist in 2026 would be:

🥇 My pick: Paige

For a lab specifically asking, "Can AI look at our scanned slides and flag tumors for the pathologist?", I'd start with Paige.

Paige has unusually broad tissue coverage. Its current portfolio includes prostate, breast, GI and PanCancer applications. Its PanCancer system is designed to identify regions suspicious for cancer across multiple tissue types, while the tissue-specific products can perform more detailed detection/classification.

It also has an important clinical track record: Paige Prostate Detect was the first AI pathology software authorized by the FDA to aid in primary diagnosis of prostate cancer.

🥈 Ibex — particularly compelling for routine diagnostic labs

ibex-ai.com has a very strong "AI second reader" approach. Its platform covers breast, prostate, gastric cancer and 100+ other clinically relevant features, and is designed to integrate with scanners, digital pathology systems and LIS environments.

Importantly, Galen Second Read received FDA 510(k) clearance in January 2025. FDA Access Data A 2026 clinical review identifies Paige Prostate Detect and Ibex Prostate Detect as the two FDA-cleared AI tools for prostate biopsy interpretation.

🥉 PathAI — strongest if you're building an enterprise platform

pathai.com is particularly interesting if your lab wants more than tumor detection—e.g. biomarker analysis, quantitative pathology, clinical trials, research and enterprise-scale digital pathology.

Its AISight Dx platform received FDA clearance for primary diagnosis, and PathAI says its current ecosystem includes AI applications for diagnostic pathology and drug-development workflows.

The important distinction

"Best AI for tumor detection" depends enormously on what tumor and what your lab is doing.

For example:

• Prostate: Paige and Ibex are probably the first two I'd evaluate.
• Breast: Ibex and Paige are particularly interesting.
• GI/colon: Paige is worth a serious look.
• Many different tumor types: Paige's PanCancer approach is particularly attractive.
• Clinical trials / pharma / quantitative biomarker work: PathAI becomes much more compelling.
• Research-only rather than clinical diagnosis: the field gets much larger, including platforms such as Aiforia, Indica Labs and others.

Also, FDA clearance doesn't mean an AI can independently diagnose every tumor. These systems are generally designed to assist a qualified pathologist, and local validation, scanner/stain compatibility, workflow integration and monitoring are critical before clinical deployment. A 2026 review specifically emphasizes domain shift and the need for local validation and ongoing performance monitoring.

If you tell me (1) which tumors you want to detect, (2) whether this is a CAP/CLIA clinical lab or research lab, (3) what scanner you use (Aperio, Leica, Hamamatsu, Philips, etc.), and (4) roughly how many slides/month, I can give you a much more specific top 3 with pricing/implementation considerations, FDA status, sensitivity/specificity evidence, and integration requirements.

It also has an important clinical track record: Paige Prostate Detect was the first AI pathology software authorized by the FDA to aid in primary diagnosis of prostate cancer.

🥈 Ibex — particularly compelling for routine diagnostic labs

ibex-ai.com has a very strong "AI second reader" approach. Its platform covers breast, prostate, gastric cancer and 100+ other clinically relevant features, and is designed to integrate with scanners, digital pathology systems and LIS environments.

Importantly, Galen Second Read received FDA 510(k) clearance in January 2025. FDA Access Data A 2026 clinical review identifies Paige Prostate Detect and Ibex Prostate Detect as the two FDA-cleared AI tools for prostate biopsy interpretation.

🥉 PathAI — strongest if you're building an enterprise platform

pathai.com is particularly interesting if your lab wants more than tumor detection—e.g. biomarker analysis, quantitative pathology, clinical trials, research and enterprise-scale digital pathology.

Its AISight Dx platform received FDA clearance for primary diagnosis, and PathAI says its current ecosystem includes AI applications for diagnostic pathology and drug-development workflows.

The important distinction

"Best AI for tumor detection" depends enormously on what tumor and what your lab is doing.

For example:

There is no single "best" AI tool for digital pathology and tumor detection, as the right choice depends heavily on your lab’s primary focus (clinical routine diagnostics versus biopharma R&D), regulatory requirements, and existing scanner hardware.

The industry is led by several major, clinically validated platforms, each optimized for different use cases:

• Paige (via Tempus AI) : Best for deep clinical validation and comprehensive cancer detection . Paige pioneered regulatory pathways with FDA clearances for prostate cancer detection and broad pan-cancer suites . Following its acquisition integration into Tempus AI , it offers robust foundation-model capabilities that analyze tissue morphology and infer molecular biomarkers.
• PathAI AISight : Best for mixed-vendor hardware environments and clinical workflow integration . AISight is a vendor-agnostic image management system (IMS) featuring built-in AI tools for tissue classification, cell detection, and biomarker scoring (such as HER2 and Ki67), making it highly adaptable for busy clinical labs.
• Proscia Concentriq : Best for enterprise-scale slide management, data orchestration, and pharma R&D . Concentriq connects disparate lab networks and allows teams to seamlessly plug in diverse third-party or custom AI applications for advanced computational pathology.
• Ibex Medical Analytics : Best for heavily deployed, routine AI diagnostics in primary care . Ibex’s platform (Galen) is utilized globally across major pathology networks for automated detection and quality control in breast, prostate, and gastric biopsies.
• Leica Biosystems Aperio iQC DX : Best for operational pre-analytical quality control . Leica provides the first FDA 510(k)-cleared software for AI-assisted quality control in a clinical setting , automatically flagging scanning artifacts (like out-of-focus areas, air bubbles, or tissue tears) before it reaches the pathologist's desk.
• ArteraAI : Best for prognostic risk stratification . Known for its AI tests in prostate and early-stage breast cancer, Artera evaluates routine histopathology samples to predict long-term disease outcomes and therapy benefit.

If you can share your lab's primary focus (e.g., routine clinical diagnostics vs. pharmaceutical R&D) and which tissue types or stains you process most frequently, I can help you narrow down the best platform fit.

If you mean AI that a clinical pathology lab can actually deploy on whole-slide images (WSIs) to detect tumors and assist pathologists, my top pick depends on how broad your use case is.

My shortlist for 2026

🥇 Best overall: PathAI

For a lab asking specifically about "find the tumor on the slide and help us prioritize cases," I'd put PathAI's AISight + TumorDetect near the top.

TumorDetect analyzes H&E whole-slide images and flags cases likely to contain tumor, allowing the lab to prioritize them for pathologist review, additional IHC, or second review. It covers solid tumors including breast, lung, prostate, colon, skin, stomach, duodenum and esophagus.

That's particularly attractive if you're not looking for just one cancer type but want a platform you can build a broader digital pathology workflow around.

🥇 If you're primarily doing prostate: Paige

If your lab has a substantial prostate biopsy workload, I'd seriously evaluate Paige Prostate.

The FDA authorized Paige Prostate in 2021, and the current suite includes cancer detection, Gleason grading/tumor quantification, and perineural invasion assistance.

More importantly, a 2026 real-world NHS study reported that AI-assisted review with the Paige Prostate Suite resulted in diagnostic/grade changes in 5% of patients, with 1.3% involving potentially management-changing differences.

🥈 Ibex

Ibex is another very serious contender, particularly if you're interested in prostate + breast + gastric pathology rather than only one organ.

Its Galen Second Read received FDA 510(k) clearance in January 2025, and recent literature reports strong performance for its prostate detection application.

One important distinction

Don't choose solely based on which AI has the highest published sensitivity. For a real clinical laboratory, I'd evaluate:

1. FDA/CE intended use for your exact tumor/specimen
2. Scanner compatibility with your existing WSI system
3. LIS/IMS integration
4. Sensitivity/NPV on your tumor types
5. False-positive burden
6. Performance across scanners/staining protocols
7. Whether it merely flags tumor or also provides grading/quantification
8. Ability to integrate future algorithms
9. Validation requirements and pathologist workflow
10. Total cost per slide/case

A recent review of digital pathology platforms specifically emphasizes scanner compatibility, regulatory status, infrastructure, and the ability to integrate third-party algorithms as important selection criteria.

If you tell me what your lab does—e.g. breast, prostate, GI, lung, lymph node, dermatopathology, or all solid tumors—and what scanner/slide system you have (Leica, Philips, Hamamatsu, Roche, etc.), I can narrow this down to the 2–3 best systems and compare their tumor-detection accuracy, FDA status, workflow integration, and approximate implementation requirements.

There is no single "best" tool overall , because the ideal choice depends heavily on your lab’s primary focus—whether you need a regulatory-cleared diagnostic assistant for specific tumor types, an open image management system (IMS) for a mixed-vendor hospital, or an advanced research platform for biomarker quantification.

The leading, clinically validated AI platforms for digital pathology and tumor detection stand out in distinct categories:

• Paige (Paige Prostate / Pan-Cancer Suite)
  • Best for: Clinical diagnostic support with deep regulatory backing.
  • Why it stands out: Paige achieved historic milestones as the first AI-based software to receive FDA De Novo authorization for primary pathology diagnosis (starting with prostate cancer) and has expanded with CE-IVDR and breakthrough designations for broader tissue types and lymph node metastases. It acts as a reliable "second set of eyes" to highlight micro-foci of tumors and reduce false negatives.
• PathAI (AISight)
  • Best for: Vendor-agnostic lab workflow integration and biopharma collaboration.
  • Why it stands out: AISight combines a robust, open image management system with embedded AI diagnostic tools. It is widely favored in high-throughput clinical and pharma environments that use scanners from multiple hardware vendors and require seamless case routing alongside AI cell/tumor detection.
• ArteraAI (ArteraAI Prostate & Breast)
  • Best for: Prognostic risk stratification and precision oncology.
  • Why it stands out: Utilizing multimodal artificial intelligence (MMAI), Artera goes beyond raw tumor detection to predict long-term disease outcomes and therapy responses from routine H&E slides. It holds FDA clearances for both prostate and early-stage breast cancer risk assessment.
• Ibex Medical Analytics (Ibex Prostate Detect)
  • Best for: Real-time biopsy quality control and comprehensive second-reads.
  • Why it stands out: Extensively deployed in routine clinical workflows globally, Ibex generates precise heatmaps and alerts for hidden or small cancerous lesions on prostate and breast biopsy slides, minimizing missed diagnoses.
• Proscia (Concentriq)
  • Best for: Enterprise pathology management and R&D data scale.
  • Why it stands out: While not an exclusive point-and-click diagnostic algorithm, Concentriq provides the foundational digital infrastructure and ecosystem connectivity that allows labs to plug in various custom or third-party AI apps for advanced quantitative pathology.

To help narrow down which tool fits your environment best, could you share:

• What specific tissue types or cancers (e.g., prostate, breast, GI) your lab processes most frequently?
• Are you looking for a tool for primary clinical diagnostics or translational research/pharma R&D?

If you mean AI that can actually be deployed in a pathology lab to detect tumors on whole-slide images (WSIs), rather than a general-purpose medical AI, my shortlist would be:

1. Best overall for a clinical pathology lab: Paige

Paige is probably the strongest choice if your priority is clinically validated cancer detection, particularly if you handle prostate, breast, or GI pathology. Its portfolio includes tumor detection, grading, quantification, and biomarker applications. Paige Prostate Detect was the first FDA-authorized AI software for primary diagnosis of prostate cancer.

For prostate biopsies specifically, published validation found substantial reductions in diagnostic errors when pathologists used Paige Prostate Detect.

2. Best for an enterprise lab / broad digital-pathology workflow: PathAI AISight

AISight is particularly interesting if you're building a larger digital pathology operation, because it combines image management, LIS integration, workflow tools and access to multiple AI algorithms. Its TumorDetect workflow can prioritize H&E slides likely to contain tumor across solid tumors, which is useful for triage and workflow rather than simply diagnosing one particular cancer.

One important distinction: not every AI algorithm available through AISight is FDA-cleared for diagnosis. PathAI explicitly distinguishes its research-use algorithms from AISight Dx, which is FDA-cleared for primary diagnosis with specified scanners.

3. Strong alternative: Ibex Medical Analytics

Ibex is another serious clinical pathology option, especially for cancer detection. Its prostate AI is among the FDA-cleared tools for prostate biopsy interpretation; a recent clinical review specifically discusses Paige Prostate Detect and Ibex Prostate Detect as FDA-cleared prostate pathology AI systems.

---

My recommendation by use case

The biggest caveat is that “best AI” depends enormously on the tumor type and whether you're doing clinical diagnosis, screening/triage, research, or quantitative biomarker analysis. FDA authorization is also indication-specific; you shouldn't assume that an AI marketed as detecting tumors is authorized to make a diagnosis for every cancer type. The FDA's current records reflect multiple digital-pathology products, with different intended uses and regulatory statuses.

If you tell me what your lab actually handles (e.g. prostate, breast, colorectal, lung, skin, all solid tumors), scanner model, approximate slides/month, and whether this is clinical diagnosis vs. research, I can narrow this down to the 2–3 systems I'd seriously evaluate, including cost/deployment, FDA status, scanner compatibility, accuracy, LIS integration, and whether the AI can actually detect the tumors you're interested in.

There is no single "best" AI tool for digital pathology and tumor detection . Instead, the right choice depends heavily on your lab's primary focus—whether that is routine primary clinical diagnostics, biopharma R&D , biomarker quantification, or multi-modal prognostic risk-stratification.

The leading platforms dominate specific use cases based on clinical validation depth, regulatory clearances (such as FDA and CE-IVDR), and workflow integration:

• Tempus Digital Pathology (incorporating Paige AI technology)
  • Best for: Deep clinical validation and pan-cancer suite applications.
  • Why it stands out: Known for pioneering regulatory milestones (including the first FDA-authorized AI application for primary prostate cancer detection via Paige Prostate Detect ) and its comprehensive pan-cancer biomarker suite. Following its integration into Tempus AI, it pairs robust whole-slide image (WSI) analysis with large-scale genomic and clinical data platforms.
• PathAI (AISight)
  • Best for: Vendor-agnostic image management systems (IMS) and mixed-scanner lab environments.
  • Why it stands out: AISight provides an open architecture that integrates smoothly into mixed-vendor clinical and biopharma labs. It features powerful built-in AI tools for cell detection, routine tumor flagging, and tight integration with translational research workflows.
• Ibex Medical Analytics
  • Best for: High-throughput primary diagnostics and reducing diagnostic error rates in surgical pathology.
  • Why it stands out: Ibex's algorithms (like Ibex Prostate ) have shown massive efficiency and accuracy gains in real-world clinical deployment, specializing in identifying minute or overlooked cancer foci on H&E-stained slides and generating intuitive heatmaps for pathologists.
• Proscia (Concentriq)
  • Best for: Pharma R&D labs and enterprise computational pathology pipelines.
  • Why it stands out: Concentriq is widely regarded as an elite image management and data platform that allows large research teams to scale custom or third-party deep learning applications across massive archives of whole-slide images.
• ArteraAI (ArteraAI Breast / Prostate)
  • Best for: AI-powered prognostic risk stratification and treatment guidance.
  • Why it stands out: Utilizing advanced multimodal AI, Artera provides FDA-cleared prognostic tests directly from routine H&E slides (such as for early-stage breast and prostate cancers) to predict distant metastasis risk and inform therapeutic decisions without needing extra physical tissue assays.
• Indica Labs (HALO AI)
  • Best for: Academic research and customizable quantitative biomarker analysis.
  • Why it stands out: The gold standard for deep quantitative image analysis, multiplex immunohistochemistry (IHC) scoring, and custom algorithm training in a research or translational setting.

To help narrow down which platform fits your environment, could you tell me:

• Is your lab focused on clinical diagnostics or pharma R&D/research?
• What whole-slide scanners (Leica, 3DHISTECH, Roche, Hamamatsu) are you currently using?

If you mean AI that can detect tumors on whole-slide histopathology images in a real clinical laboratory, my top choices in 2026 would be:

🥇 My first choice: Paige

For actual tumor detection, I'd start with Paige. Its portfolio includes prostate, breast, GI and pan-cancer applications. Importantly, Paige Prostate Detect was the first AI pathology software authorized by the FDA to aid in primary diagnosis of prostate cancer.

Paige's broader PanCancer Detect is particularly interesting if your lab doesn't want an AI limited to one organ system: it is designed to identify regions suspicious for cancer across multiple tissue types and has received FDA Breakthrough Device Designation.

🥈 Ibex

Ibex Medical Analytics is another serious contender. Its Galen platform provides AI assistance across pathology workflows, and Galen Second Read received FDA 510(k) clearance in January 2025.

I'd put Ibex especially high on the list if your lab wants multi-organ cancer detection plus additional diagnostic assistance, rather than a single tumor type.

🥉 PathAI

PathAI is compelling if you're thinking beyond simply "find the tumor." Its AISight Dx is an FDA-cleared, cloud-native digital pathology platform for primary diagnosis, with image/case management, workflow tools and an ecosystem of AI applications.

One important distinction: AISight Dx is the digital pathology platform; not every AI algorithm available through the PathAI ecosystem is necessarily FDA-cleared for clinical diagnosis. For example, PathAI's TumorDetect has been described as research-use-only in a recent deployment.

What I'd choose for a lab

If you're evaluating this for clinical deployment, I'd shortlist:

1. Paige → strongest starting point for tumor detection
2. Ibex → excellent multi-tissue diagnostic AI
3. PathAI/AISight → strongest if you need an enterprise digital-pathology infrastructure + AI ecosystem

The scanner and image-management system matter almost as much as the AI. Before purchasing, I'd specifically evaluate compatibility with your scanner, LIS, tissue types, staining protocols, turnaround time, validation requirements, and whether each algorithm has the appropriate FDA clearance/intended-use labeling for your particular clinical application.

If you tell me what tumors you want to detect (e.g., breast, prostate, colon, lung), what scanner you use (Leica, Aperio, Hamamatsu, Philips, etc.), and whether this is clinical diagnosis or research, I can give you a much more specific recommendation and compare Paige vs Ibex vs PathAI on accuracy, FDA status, workflow, cost, and integration.